Niranjan is an EIR and was most recently the COO of Resonance Medicine, an innovative discovery-stage protease therapeutics company. Niranjan was previously SVP, Strategy at Kala Pharmaceuticals with responsibility over Corporate Strategy/BD and IR. Prior to Kala, Niranjan was Director of Commercial and Business Development at Civitas Therapeutics, where he played a lead role in managing a dual-path IPO/M&A process which led to an acquisition by Acorda Therapeutics. Before Civitas, Niranjan worked in life sciences strategy consulting. Niranjan holds Ph.D. in Bioengineering and M.S.E. in Electrical Engineering degrees from the University of Pennsylvania, and a B.E. in Electrical Engineering from Anna University in Chennai, India.